PICI Network In the News | Recent Highlights

PICI Network In the News | Recent Highlights

The?Parker Institute for Cancer Immunotherapy?(PICI) is committed to turning all cancers into curable diseases faster, with a relentless focus on science, collaboration, patients and bold action. The PICI Network gives life to this pursuit, pushing novel immunotherapy research forward with partnerships, events, awards and individual accomplishments.

Every month, we?round?up?PICI Network?news?to highlight collaborations between researchers, nonprofits and industry, highlighting the impact of our collective pursuits on the field.

Read on for?recent achievements.?

Research Advances?

CAR-T Therapy Doesn’t Work in All Cancer Cases. Scientists Are Starting to Figure Out Why.

STAT | Oct. 4, 2022

Researchers are beginning to work out why more than half of lymphoma patients treated with CAR-T therapy don’t experience lasting remission, depending on the product.

The article covers these Nature Medicine papers:

Newly Discovered Immune Cells Shed Light on Formation of Healthy Relationship with Gut Bacteria

Memorial Sloan Kettering Cancer Center | Oct. 13, 2022

A newly discovered class of immune cell — Thetis cells — plays a key role in establishing a harmonious relationship between infants and the helpful microbes in their digestive systems. The work also raises the possibility of roles for Thetis cells in tolerance to other types of foreign antigens, as well as self-antigens, which could be important for cancer immune responses.

Neoadjuvant Immunotherapy with Relatlimab and Nivolumab is Safe and Effective in Stage III Melanoma

The University of Texas MD Anderson Cancer Center | Oct. 26, 2022

Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, MD Anderson researchers?report.

Genomic Sequencing of Bladder and Urachal Adenocarcinoma may Identify Actionable Alterations to Guide Therapy

MedPage Today | Oct. 27, 2022

In a study funded in part by PICI, researchers at Memorial Sloan Kettering compared oncologic outcomes and genomic alteration profiles in glandular variants in bladder cancer, potentially shedding new light on more effective treatments.

Industry News

CAR-T Pioneer Carl June, MD, on Founding Startups and Cell Therapy’s Next Act BioPharma

BioPharma Dive | Oct. 18, 2022

The University of Pennsylvania immunologist and Kymriah inventor spoke with BioPharma Dive about working with pharma, starting companies and the future of cell therapy.

3T Biosciences Announces Appointment to Board of Directors

3T Biosciences | Oct. 25, 2022

John Leonard, MD, president and CEO of Intellia Therapeutics, joins the board of the PICI-backed biotech.

Biotech’s Newest Odd Couple: A Pharma Insider and a Music Maven Launch a Health-care VC

STAT | Oct. 26, 2022

Tim Wright and D.A. Wallach have become biotech’s newest odd couple, launching health-care VC firm Time BioVentures, which boasts an eclectic mix of advisers and investors, including Sean Parker and Jim Allison.

Using Herpes Virus Vectors, Paul Peter Tak and Carl June Team Up to Solve the CAR-T Solid Tumor Challenge

Endpoints News | Oct. 26, 2022

Candel Therapeutics is joining forces with Carl June’s lab at the University of Pennsylvania to see if the herpes virus can boost the effectiveness of CAR-T therapies in solid tumors, the biotech led by Paul Peter Tak announced.

Grants & Awards

Chris Garcia, Hani Goodarzi Receive NIH Transformative Research Awards

National Institutes of Health?| Oct. 4, 2022

Two PICI Network members have been awarded?High-Risk, High-Reward Research program?grants from the NIH in recognition of unconventional, boundary-pushing work focused on challenges in biomedical research.

Recipients of the?Transformative Research Awards?are:

Crystal Mackall, MD, Elected to National Academy of Medicine

National Academy of Medicine | Oct. 17, 2022

The Parker Institute for Cancer Immunotherapy congratulates Crystal Mackall, MD, for her election to the National Academy of Medicine. Dr. Mackall is recognized for “pioneering immune therapies for children’s cancers, and for discovering fundamental principles of human immunology and translating these insights into cutting-edge engineered cell therapies for cancer.”

Read the Stanford Medicine press release?here.

Center News

UCSF Hosts First Lady Jill Biden to Discuss Breast Cancer Research

University of California, San Francisco | Oct. 7, 2022

First Lady Jill Biden, PhD, met with top UC San Francisco cancer leaders during a visit to hear about the institution’s breast cancer research and progress on the National Cancer Moonshot.

Dana-Farber at the top of the 2022 Top 100 Women-Led Businesses in Massachusetts

Dana-Farber Cancer Institute | Oct. 28, 2022

Dana-Farber and Laurie Glimcher, MD, president and CEO, are No.1 on the 2022 Top 100 Women-Led Businesses in Massachusetts list.

Research Meetings

Yvonne Chen Discusses Biospecific CAR Proteins to “Wake Up”?the Immune Systems of Cancer Patients

Pharmacy Times | Oct. 5, 2022

In two interviews recorded at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference, Yvonne Chen, PhD, of UCLA discusses:

PICI Network Researchers to Present at SITC

Parker Institute for Cancer Immunotherapy | Oct. 21, 2022

PICI Network investigators will present the latest in immuno-oncology research at the 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer, Nov. 8-12 in Boston and online.

要查看或添加评论,请登录

Parker Institute for Cancer Immunotherapy的更多文章

社区洞察

其他会员也浏览了